Cipla Limited (NSE: CIPLA | BSE: 500087)

By Raveendran R | Updated on:

Source: Cipla Limited Integrated Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners

Cipla Limited is a global pharmaceutical powerhouse, ranking as the 3rd largest pharmaceutical company in India, the 2nd largest player in the South African prescription market, the 2nd largest Indian exporter to emerging markets, the 4th largest Indian exporter to Europe, and the 3rd largest supplier by prescription for generic inhalation products in the United States. Operating with an overarching mission of ‘Caring for Life’ , Cipla develops, manufactures, and commercialises a comprehensive portfolio of over 1,500 pharmaceutical products across 50+ dosage forms, catering to patients in 69 key commercial markets worldwide.

CORE BUSINESS SEGMENTS:
  • Annual Production Scale: 25 Billion Tablets & Capsules, 569 Million Respules, 150.3 Million Aerosol MDIs, 46.5 Million Oral Liquids, 45.3 Million Nasal Sprays, 3.4 Million Dry Powder Inhalers (Ciphalers), 0.15 Million Lyophilised Injections, and 792 Tonnes of APIs.
  • Inhalation Market Leadership: Cipla commands ~26% overall market share in the Indian respiratory segment, ~62% share in covered inhalation formulations, and ~75% share in covered nebulisation segments. In the US, generic Albuterol HFA holds a 19.6% market share with over 67 million cumulative inhalers shipped.
  • Regulatory & Filing Pipeline: Cumulative 285 ANDAs & NDAs filed with US FDA (79 Under Approval/Tentative Approval, 10 new filings in FY26); 2,824 cumulative Drug Master Files (DMFs) globally including 169 US DMFs; 281 active granted patents.
  • Customer Concentration (Ind AS 108): No single external customer accounts for 10% or more of Cipla’s total consolidated revenue, reflecting a highly diversified institutional and wholesale customer base.
Metrics for FY 2025-26 Ended Mar 31, 2026
PROFIT & LOSS METRICS (₹ CR)
Revenue
₹28,162.59 Cr (▲ 2.2%)
Prev Year: ₹27,547.62 Cr
Gross Profit
₹18,613.48 Cr (- 0.0%)
Prev Year: ₹18,618.63 Cr
Operating Profit
₹4,671.92 Cr (▼ 22.4%)
Prev Year: ₹6,020.95 Cr
Net Profit
₹3,861.74 Cr (▼ 26.7%)
Prev Year: ₹5,269.20 Cr
Gross Margin
66.09 % (▼ 149 bps)
Prev Year: 67.59 %
Operating Margin
16.59 % (▼ 527 bps)
Prev Year: 21.86 %
PAT Margin
13.71 % (▼ 542 bps)
Prev Year: 19.13 %
Asset Turnover
0.66x (▼ 0.07 pts)
Prev Year: 0.74x
RETURN & CAPITAL EFFICIENCY METRICS
ROE
11.19 % (▼ 565 bps)
Prev Year: 16.84 %
ROCE
13.17 % (▼ 571 bps)
Prev Year: 18.87 %
ROA
9.09 % (▼ 501 bps)
Prev Year: 14.09 %
Cash ROE
11.41 % (▼ 458 bps)
Prev Year: 16.00 %
Cash ROCE
11.10 % (▼ 458 bps)
Prev Year: 15.69 %
BALANCE SHEET METRICS (₹ CR)
Total Assets
₹42,495.98 Cr (▲ 13.7%)
Prev Year: ₹37,387.04 Cr
Current Assets
₹24,145.86 Cr (▲ 3.9%)
Prev Year: ₹23,248.97 Cr
Total Liabilities
₹7,975.74 Cr (▲ 30.8%)
Prev Year: ₹6,097.79 Cr
Current Liabilities
₹7,013.59 Cr (▲ 27.9%)
Prev Year: ₹5,483.96 Cr
Total Equity
₹34,520.24 Cr (▲ 10.3%)
Prev Year: ₹31,289.25 Cr
Working Capital
₹17,132.27 Cr (▼ 3.6%)
Prev Year: ₹17,765.01 Cr
Current Ratio
3.44x (▼ 0.80 pts)
Prev Year: 4.24x
Total Debt
₹257.97 Cr (▲ 180.1%)
Prev Year: ₹92.10 Cr
Debt to Equity
0.01x (- 0.00 pts)
Prev Year: 0.00x
Debt to Assets
0.01x (- 0.00 pts)
Prev Year: 0.00x
Equity Multiplier
1.23x (▲ 0.04 pts)
Prev Year: 1.19x
CASH FLOW METRICS (₹ CR)
Operating Cash Flow
₹3,940.02 Cr (▼ 21.3%)
Prev Year: ₹5,004.98 Cr
CapEx
₹1,599.33 Cr (▲ 37.6%)
Prev Year: ₹1,162.16 Cr
Free Cash Flow
₹2,340.69 Cr (▼ 39.1%)
Prev Year: ₹3,842.82 Cr
FCF Margin
8.31 % (▼ 564 bps)
Prev Year: 13.95 %
CF to Debt
15.27x (▼ 39.07 pts)
Prev Year: 54.34x
ROCE (6Y Avg)
20.42 %
FY21–FY26 (6Y Avg)
ROE (6Y Avg)
13.44 %
FY21–FY26 (6Y Avg)

📋 Quick Facts / Company Snapshot: Cipla Limited (NSE: CIPLA | BSE: 500087)

Attribute Disclosed Detail
Official Company Name Cipla Limited
Corporate Identity Number (CIN) L24239MH1935PLC002380
International Securities Identification Number (ISIN) INE059A01026
Stock Exchange Listing NSE Symbol: CIPLA | BSE Scrip Code: 500087 | Luxembourg Stock Exchange (GDRs): CIPLG / 1729772095
Date of Incorporation / Founding Year August 17, 1935 (90-Year Operational Legacy)
Founders / Key Founding Figures Dr. K. A. Hamied (1898–1972)
Registered Office & Corporate Headquarters Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400 013, Maharashtra, India
Contact Phone & Investor Email Tel: +91 22 41916000 | Email: cosecretary@cipla.com / investor.relations@cipla.com
Non-Executive Chairman Dr. Y. K. Hamied
Vice-Chairman & Lead Independent Director Mr. P. R. Ramesh
Managing Director & Global CEO (MD & GCEO) Mr. Achin Gupta (Appointed w.e.f. April 1, 2026, succeeding Mr. Umang Vohra)
Global Chief Financial Officer (CFO) Mr. Ashish Adukia
Company Secretary & Compliance Officer Mr. Rajendra Chopra
Promoter & Holding Group Hamied Family (Dr. Y. K. Hamied, Mr. M. K. Hamied, Ms. Sophie Ahmed, Mr. Kamil Hamied) — 29.12% Combined Stake
Industry / Sector Classification Pharmaceuticals & Life Sciences (NIC Codes: 210002 – Allopathic Formulations, 464907 – Wholesale Trade, 210001 – Active Pharmaceutical Ingredients)
Total Workforce / Employee Base 31,000+ Permanent Employees & Workers globally across 18 countries (26,388 Permanent Employees on Standalone rolls; 16.85% female representation)
Manufacturing Network & Operational Footprint 48 cGMP-compliant facilities globally across 5 countries (39 India, 9 International); 105 total offices and plants across 69 global markets
Credit Ratings & Rating Agencies Commercial Paper: IND A1+ / IND AAA (Stable) by India Ratings; Long-Term / Short-Term Bank Facilities: CARE A1+ / CARE AAA (Stable) by CARE Ratings
Statutory & Secretarial Auditors Statutory Auditor: M/s Walker Chandiok & Co LLP (retiring) / M/s B S R & Co. LLP (appointed for 5-year term from 90th AGM) | Secretarial Auditor: M/s BNP & Associates
Cost Auditor & Registrar (RTA) Cost Auditor: M/s Joshi Apte & Associates | Registrar & Share Transfer Agent: KFin Technologies Limited

🏢 The Corporate Identity: Cipla Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Cipla Limited is a global pharmaceutical powerhouse, ranking as the 3rd largest pharmaceutical company in India, the 2nd largest player in the South African prescription market, the 2nd largest Indian exporter to emerging markets, the 4th largest Indian exporter to Europe, and the 3rd largest supplier by prescription for generic inhalation products in the United States. Operating with an overarching mission of ‘Caring for Life’, Cipla develops, manufactures, and commercialises a comprehensive portfolio of over 1,500 pharmaceutical products across 50+ dosage forms, catering to patients in 69 key commercial markets worldwide.

The company’s business model is anchored across four foundational geographic pillars: One India (comprising Branded Prescriptions, Trade Generics, and Consumer Health), North America (focused on complex generics, respiratory inhalers, injectables, and biosimilars), One Africa (private prescription leadership, OTC, and access programs), and Emerging Markets & Europe (EMEU). Cipla’s global competitive edge stems from its respiratory drug-device integration capabilities, extensive manufacturing scale across 48 Current Good Manufacturing Practices (cGMP) facilities, and robust research and development (R&D) engine focused on complex molecules, peptide injectables, biosimilars, and novel therapeutic modalities.

The Founders, Promoters & Their Legacy

Cipla was founded in August 1935 by the visionary scientist and industrialist Dr. K. A. Hamied (1898–1972) as ‘The Chemical, Industrial & Pharmaceutical Laboratories Limited’, establishing India’s indigenous pharmaceutical manufacturing foundation to achieve national self-reliance in healthcare. Under the subsequent leadership of Dr. Y. K. Hamied (Non-Executive Chairman) and Mr. M. K. Hamied, Cipla reshaped global public health paradigms—most notably in 2001 by introducing the world’s first triple anti-retroviral (ARV) therapy (Stavudine + Lamivudine + Nevirapine) at less than $1 per day in Africa, transforming HIV/AIDS treatment across developing nations.

The promoter group, comprising Dr. Y. K. Hamied, Mr. M. K. Hamied, Ms. Sophie Ahmed, and Mr. Kamil Hamied, holds a collective 29.12% equity stake (23,52,87,003 equity shares) in Cipla Limited as of March 31, 2026. The promoters maintain strict stewardship over the company’s strategic vision, supported by institutional governance and professional executive management led by Managing Director and Global CEO Mr. Achin Gupta, who assumed leadership on April 1, 2026, following a structured succession from Mr. Umang Vohra.

The Journey: Corporate History & Key Milestones

Spanning nine decades of healthcare innovation, Cipla’s major operational and strategic milestones include:

  • 1935: Incorporated in Mumbai as The Chemical, Industrial & Pharmaceutical Laboratories Limited by Dr. K. A. Hamied.
  • 1970: Pioneered the development of indigenous Active Pharmaceutical Ingredients (APIs) and supported the formulation of the Indian Patents Act, 1970, laying the groundwork for India’s generic pharma industry.
  • 1991: Launched India’s first indigenously developed Metered Dose Inhaler (MDI) for asthma care, laying the foundation for global respiratory leadership.
  • 2001: Disrupted global HIV/AIDS treatment by offering triple anti-retroviral therapy at $350 per year per patient (versus $12,000 charged by global multinationals), extending treatment to millions across Africa and emerging economies.
  • 2016–2020: Expanded North American front-end commercial presence through the acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals; scaled generic Albuterol HFA inhaler to achieve a top-3 market ranking in the United States.
  • FY 2025–26: Celebrated 90 years of operations with the launch of India’s first rapid-acting inhaled insulin (Afrezza), entry into GLP-1/GIP obesity care (Yurpeak/Tirzepatide in partnership with Eli Lilly), approval of the first AB-rated generic Ventolin (gVentolin) MDI in the US, and revenue scaling to ₹28,162.59 Crores.

The Corporate Umbrella & Group Structure

Cipla Limited operates through a global group network comprising wholly owned operating subsidiaries, step-down international subsidiaries, joint ventures, and strategic associates. Key corporate entities include:

  • Cipla Health Limited (CHL): Wholly owned Indian consumer health subsidiary driving iconic healthcare brands including Omnigel, Nicotex, Cipladine, Cofsils, and Prolyte.
  • Cipla Pharma and Life Sciences Limited: Wholly owned Indian subsidiary operating the country’s largest Trade Generics business across 1.5 Lakh+ retail pharmacies.
  • Inzpera Healthsciences Limited: Wholly owned Indian subsidiary (acquired on December 4, 2025) specializing in pediatric and wellness health.
  • Cipla (EU) Limited (UK): Wholly owned European holding subsidiary governing international front-end operations, including CiplaRna GmbH (Germany) and Cipla Middle East Company (Saudi Arabia).
  • InvaGen Pharmaceuticals Inc. & Cipla USA Inc.: Wholly owned US operational subsidiaries overseeing North American manufacturing, R&D, and commercial distribution.
  • Cipla Medpro South Africa (Pty) Limited: Wholly owned flagship African operating subsidiary anchoring prescription and OTC market leadership.
  • Aspergen Limited: Joint venture (60% Cipla / 40% Kemwell Biopharma) incorporated on May 5, 2026, focused on biosimilar development.

⚙️ The Business Engine: Cipla Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

Cipla’s business operations are structured across four primary geographical reportable business segments, alongside an Active Pharmaceutical Ingredients (API) division and Other Operating Revenues. Total revenue from operations reached ₹28,162.59 Crores in FY 2025–26, representing a 2.23% growth over ₹27,547.62 Crores in FY 2024–25.

Business Segment / Geography FY 2025-26 Revenue (₹ Cr) % Share of Total Revenue FY 2024-25 Revenue (₹ Cr) Latest YoY (%)
One-India (Branded Rx, Trade Gx, Consumer Health) 12,680.26 45.02% 11,614.67 +9.17%
North America (US & Canada) 6,871.50 24.40% 7,899.01 -13.01%
One Africa (South Africa, Sub-Saharan, CGA) 4,285.45 15.22% 3,826.48 +11.99%
Emerging Markets & Europe (EMEU) 4,325.38 15.36% 4,207.46 +2.80%
API & Other Operating Income 0.00 0.00% 0.00% –
Total Revenue from Operations 28,162.59 100.00% 27,547.62 +2.23%

The Product & Service Catalog

Cipla’s commercial portfolio covers major chronic and acute therapeutic areas including Respiratory, Cardiovascular/Cardiometabolic, Anti-Diabetes, Urology, Anti-Infectives, Central Nervous System (CNS), Oncology, Gastroenterology, Dermatology, and Ophthalmology. Key operational capabilities and portfolio metrics include:

  • Annual Production Scale: 25 Billion Tablets & Capsules, 569 Million Respules, 150.3 Million Aerosol MDIs, 46.5 Million Oral Liquids, 45.3 Million Nasal Sprays, 3.4 Million Dry Powder Inhalers (Ciphalers), 0.15 Million Lyophilised Injections, and 792 Tonnes of APIs.
  • Inhalation Market Leadership: Cipla commands ~26% overall market share in the Indian respiratory segment, ~62% share in covered inhalation formulations, and ~75% share in covered nebulisation segments. In the US, generic Albuterol HFA holds a 19.6% market share with over 67 million cumulative inhalers shipped.
  • Regulatory & Filing Pipeline: Cumulative 285 ANDAs & NDAs filed with US FDA (79 Under Approval/Tentative Approval, 10 new filings in FY26); 2,824 cumulative Drug Master Files (DMFs) globally including 169 US DMFs; 281 active granted patents.
  • Customer Concentration (Ind AS 108): No single external customer accounts for 10% or more of Cipla’s total consolidated revenue, reflecting a highly diversified institutional and wholesale customer base.

The Names You Know: Key Brands & Flagship Portfolio

Cipla owns and markets several of India’s and South Africa’s largest pharmaceutical brands, including 33 brands in India that individually generate over ₹100 Crores in annual turnover.

Brand / Product Name Category / Business Segment Target Market & Key Positioning
Foracort Respiratory (Asthma & COPD) First brand in the Indian Pharmaceutical Market (IPM) to cross ₹1,000 Crores in annual market sales; flagship Formoterol + Budesonide combination inhaler.
Duolin Respiratory (COPD & Severe Asthma) Leading combination nebuliser/inhaler therapy (Ipratropium + Levosalbutamol) generating multi-hundred Crore revenues across domestic and export markets.
Budecort Respiratory (Asthma Management) Core Budesonide corticosteroid inhaler and respule franchise catering to pediatric and adult maintenance therapy.
Dytor Cardiovascular / Cardiac Care Flagship in-house Torsemide loop diuretic franchise crossing ₹650 Crores in annual revenue with 25% YoY growth.
Montair LC Respiratory / Anti-Allergy Montelukast + Levocetirizine combination ranking among the top 50 brands in the IPM, targeting ₹400 Crores+ milestone.
Omnigel Consumer Health / Pain Relief Market-leading topical pain relief gel and spray brand generating ₹100 Crores+ in consumer health revenues.
Nicotex Consumer Health / Smoking Cessation Category-defining nicotine replacement therapy brand maintaining market leadership in smoking cessation solutions.
Cipladine Consumer Health / Antiseptic Care Leading Povidone-Iodine antiseptic ointment and liquid brand serving hospitals, pharmacies, and households.
Cofsils Consumer Health / Cough & Cold Leading consumer cough lozenge and syrup brand offering fast-acting throat relief across retail channels.
Prolyte Consumer Health / Hydration Market-leading Ready-To-Drink (RTD) Oral Rehydration Salts (ORS) energy and electrolyte drink brand.
Afrezza In-Licensed Anti-Diabetes Care India’s first rapid-acting inhaled insulin launched in partnership with MannKind Corporation for Type 1 and Type 2 diabetes.
Yurpeak In-Licensed Obesity & Diabetes Care First-in-class dual GIP and GLP-1 receptor agonist (Tirzepatide) launched in multi-dose pen format in partnership with Eli Lilly.

Mapping the Domestic & Global Reach (India vs. Exports)

Cipla maintains a balanced geographic revenue structure, deriving 45.02% of its revenues from its domestic Indian business and 54.98% from international export markets and overseas operating subsidiaries.

Geographic Region FY 2025-26 Revenue (₹ Cr) % Share of Total Revenue FY 2024-25 Revenue (₹ Cr) Key Commercial Markets & Footprint Latest YoY (%)
India (Domestic) 12,680.26 45.02% 11,614.67 28 States & 8 Union Territories; 1.5 Lakh+ retail pharmacies; 2.65 Lakh+ HCP engagements. +9.17%
United States of America 6,871.50 24.40% 7,899.01 Top-3 generic inhalation supplier; direct commercial distribution to US wholesalers & hospital chains. -13.01%
One Africa 4,285.45 15.22% 3,826.48 South Africa (Private Rx #2 rank), Morocco, Algeria, Sub-Saharan Africa (Kenya, Uganda), Global Access (CGA). +11.99%
Rest of the World / EMEU 4,325.38 15.36% 4,207.46 Nepal (#3 market rank), Sri Lanka (#3), Malaysia, China, Germany, Spain, UK, Australia, Mexico. +2.80%
Total Consolidated Revenue 28,162.59 100.00% 27,547.62 Commercial presence across 69 global markets. +2.23%

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

Cipla operates 48 cGMP-compliant manufacturing sites and 6 state-of-the-art R&D centers across 5 countries, supported by 105 national and international offices:

  • India Manufacturing Sites (39 Plants): Major clusters located at Goa (Verna, Kundaim – MDIs, Respules, Oral Solids, Cytotoxic Injectables), Maharashtra (Patalganga, Kurkumbh – APIs & Formulations; Satara, Vasai), Sikkim (Kumrek, Rorathang – Oral Solids, Respules, STPs), Madhya Pradesh (Indore SEZ – MDIs, DPIs, Oral Solids), Karnataka (Virgonagar, Bommasandra – APIs), and Himachal Pradesh (Baddi – MDIs, Synchrobreathe).
  • International Manufacturing Sites (9 Plants): United States (Fall River, Massachusetts – Green Propellant MDI plant; Central Islip & Long Island, New York – DPIs, Oral Solids); South Africa (Durban – Effervescent & Solid Dosage; Mirren); Morocco (Rabat); China (Jiangsu Province – Respules).
  • Global R&D Centers (6 Facilities): Cutting-edge research centers located in Maharashtra (Vikhroli, Mumbai & Patalganga), Karnataka (Bengaluru), New York (USA), and Germany (CiplaRna GmbH – mRNA R&D hub), employing 1,750+ scientists and researchers.

📊 The Financial Health: Cipla Financial Statements & Numbers Simplified

Multi-Year Financial Highlights

The table below presents Cipla’s multi-year consolidated financial trend over six fiscal years (FY 2020–21 through FY 2025–26), demonstrating long-term revenue scaling and structural profitability:

Financial Metric (₹ Cr) FY 2025-26 FY 2024-25 FY 2023-24 FY 2022-23 FY 2021-22 FY 2020-21 Latest YoY (%)
Revenue from Operations 28,162.59 27,547.62 25,774.00 22,753.00 21,763.00 19,160.00 +2.23%
EBITDA 5,925.00 7,128.00 6,291.00 5,027.00 4,578.00 4,303.00 -16.88%
EBITDA Margin (%) 21.04% 25.87% 24.41% 22.09% 21.03% 22.46% –
Profit After Tax (Owners) 3,861.74 5,269.20 4,122.00 2,802.00 2,517.00 2,405.00 -26.71%
PAT Margin (%) 13.77% 19.14% 15.99% 12.31% 11.57% 12.55% –
Total Equity (Owners) 34,520.24 31,289.25 26,706.00 23,408.00 20,842.00 18,327.00 +10.33%
Diluted EPS (₹) 48.00 65.24 51.01 34.69 31.17 29.79 -26.43%

Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)

The following table provides the audited Consolidated Statement of Profit and Loss of Cipla Limited for FY 2025–26 compared with FY 2024–25 in Ind AS Schedule III format:

Statement of Profit and Loss (₹ in Crores) FY 2025-26 FY 2024-25 Latest YoY (%)
I. Income
Revenue from Operations (Sale of Products & Operating Revenues) 28,162.59 27,547.62 +2.23%
Other Income 882.01 861.87 +2.34%
Total Income 29,044.60 28,409.49 +2.24%
II. Expenses
Cost of Materials Consumed 5,841.62 5,409.60 +7.99%
Purchases of Stock-in-Trade 4,451.37 3,851.49 +15.58%
Changes in Inventories of Finished Goods, WIP & Stock-in-Trade -743.88 -332.10 +123.99%
Employee Benefits Expense 5,366.33 4,832.83 +11.04%
Finance Costs 54.39 62.01 -12.29%
Depreciation, Impairment and Amortisation Expense 1,210.98 1,106.95 +9.40%
Impairment of Investment in Associates 42.02 0.00 N/M
Other Expenses (R&D, Sales & Marketing, Manufacturing, Logistics) 7,322.23 6,657.90 +9.98%
Total Expenses 23,545.06 21,588.68 +9.06%
EBITDA (Calculated: Revenue – Operating Expenses) 5,925.00 7,128.00 -16.88%
Operating Profit (EBIT: PBT + Finance Costs – Other Income) 4,671.92 6,020.95 -22.41%
Profit Before Exceptional Items & Tax 5,499.54 6,820.81 -19.37%
Exceptional Item – (Loss on New Labour Codes Provision) -275.91 0.00 N/M
Profit Before Tax (PBT) 5,223.63 6,820.81 -23.42%
Tax Expense: Current Tax 1,440.95 1,708.35 -15.65%
Tax Expense: Deferred Tax (Credit) -87.11 -178.59 -51.22%
Total Tax Expense 1,353.84 1,529.76 -11.50%
Net Profit After Tax before Share of Associates 3,861.74 5,291.05 -27.01%
Share of Profit / (Loss) of Associates -8.05 -21.85 -63.16%
Net Profit for the Year (Consolidated PAT) 3,861.74 5,269.20 -26.71%
Profit Attributable to Owners of the Parent 3,879.23 5,272.52 -26.43%
Profit / (Loss) Attributable to Non-Controlling Interest -17.49 -3.32 +426.81%
Other Comprehensive Income / (Loss) (Net of Tax) 687.74 218.66 +214.52%
Total Comprehensive Income for the Year 4,549.48 5,487.86 -17.10%
Basic Earnings Per Share (₹) 48.03 65.29 -26.44%
Diluted Earnings Per Share (₹) 48.00 65.24 -26.43%

Revenue growth in FY 2025–26 was driven by consistent operational traction in One-India (+9.17% YoY) and One Africa (+11.99% YoY). Overall EBITDA and PAT declined compared to FY 2024–25 due to high baseline earnings in FY 2024–25 (which included generic Revlimid g-exclusivity sales in North America), increased planned investments in R&D (₹1,974.00 Crores, 7.0% of revenue), higher employee costs (+11.04%), an exceptional charge of ₹275.91 Crores due to past service gratuity and leave encashment provisions under the New Labour Codes, and an impairment of associate investments (₹42.02 Crores).

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

The audited Consolidated Balance Sheet of Cipla Limited as of March 31, 2026, compared with March 31, 2025, is detailed below:

Consolidated Balance Sheet (₹ in Crores) As at March 31, 2026 As at March 31, 2025 Latest YoY (%)
ASSETS
(1) Non-Current Assets
Property, Plant and Equipment 5,586.66 4,813.88 +16.05%
Right-of-use Assets 453.14 448.38 +1.06%
Capital Work-in-Progress (CWIP) 1,586.28 1,212.76 +30.80%
Investment Property 0.00 111.25 -100.00%
Goodwill 3,754.42 3,270.27 +14.80%
Other Intangible Assets 2,640.14 1,362.61 +93.76%
Intangible Assets Under Development 455.94 353.51 +28.98%
Investment in Associates 111.75 140.47 -20.45%
Non-Current Financial Assets – Investments 432.24 499.07 -13.39%
Non-Current Financial Assets – Loans 2.76 32.54 -91.52%
Non-Current Financial Assets – Other Financial Assets 1,194.10 283.46 +321.26%
Non-Current Tax Assets (Net) 573.28 487.86 +17.51%
Deferred Tax Assets (Net) 901.02 644.87 +39.72%
Other Non-Current Assets 657.22 437.59 +50.19%
Total Non-Current Assets 18,348.95 14,098.52 +30.15%
(2) Current Assets
Inventories 6,596.72 5,642.11 +16.92%
Current Financial Assets – Investments 7,679.42 7,293.23 +5.30%
Current Financial Assets – Trade Receivables 5,620.05 5,506.37 +2.06%
Current Financial Assets – Cash and Cash Equivalents 1,018.22 588.69 +72.96%
Current Financial Assets – Other Bank Balances 289.20 211.15 +36.96%
Current Financial Assets – Loans 23.12 15.64 +47.83%
Current Financial Assets – Other Financial Assets 1,460.23 2,936.90 -50.28%
Other Current Assets 1,458.90 1,054.88 +38.30%
Total Current Assets 24,145.86 23,248.97 +3.86%
Assets Classified as Held for Sale 1.17 39.55 -97.04%
TOTAL ASSETS 42,495.98 37,387.04 +13.67%
EQUITY AND LIABILITIES
(1) Equity
Equity Share Capital 161.56 161.52 +0.02%
Other Equity 34,270.39 31,031.93 +10.44%
Equity Attributable to Owners of Parent 34,431.95 31,193.45 +10.38%
Non-Controlling Interest 88.29 95.80 -7.84%
TOTAL EQUITY (NET WORTH) 34,520.24 31,289.25 +10.33%
(2) Liabilities
Non-Current Liabilities
Non-Current Borrowings 117.47 11.98 +880.55%
Non-Current Lease Liabilities 264.48 240.49 +9.98%
Other Financial Liabilities (Non-Current) 220.40 102.39 +115.26%
Non-Current Provisions 157.56 148.69 +5.97%
Deferred Tax Liabilities (Net) 153.27 53.53 +186.33%
Other Non-Current Liabilities 48.97 56.75 -13.71%
Total Non-Current Liabilities 962.15 613.83 +56.75%
Current Liabilities
Current Borrowings 140.50 80.12 +75.36%
Current Lease Liabilities 91.32 105.60 -13.52%
Trade Payables – MSME Creditors 215.18 278.60 -22.76%
Trade Payables – Other Than MSME Creditors 3,014.72 2,558.89 +17.81%
Other Financial Liabilities (Current) 986.77 374.54 +163.46%
Other Current Liabilities 300.50 292.85 +2.61%
Current Provisions 2,259.15 1,716.61 +31.61%
Current Tax Liabilities (Net) 5.45 76.75 -92.90%
Total Current Liabilities 7,013.59 5,483.96 +27.89%
Total Liabilities (Non-Current + Current Liabilities) 7,975.74 6,097.79 +30.80%
TOTAL EQUITY AND LIABILITIES 42,495.98 37,387.04 +13.67%

Working Capital Cycle & Statutory Ratios

Cipla maintains a highly liquid, fortress balance sheet characterised by net cash surplus, strong working capital ratios, and minimal financial leverage:

Key Statutory Financial Ratio FY 2025-26 FY 2024-25 Latest YoY (%)
Debtors’ Turnover Ratio 5.10x 5.40x -5.56%
Inventory Turnover Ratio 1.60x 1.60x 0.00%
Current Ratio 3.40x 4.20x -19.05%
Debt-Service Coverage Ratio (DSCR) 35.80x 55.20x -35.14%
Interest Coverage Ratio 108.90x 114.90x -5.22%
Operating Profit Margin (%) 16.59% 21.86% –
Net Profit Margin (%) 3,861.74 19.14% –
Return on Net Worth (RoNW) (%) 11.80% 18.20% –
Net Debt-to-Equity Ratio -0.31x -0.32x -3.12%

Cash Flow: Tracking the Money Movement

The audited Consolidated Statement of Cash Flows for FY 2025–26 compared with FY 2024–25 is detailed below:

Consolidated Cash Flow Statement Summary (₹ in Crores) FY 2025-26 FY 2024-25 Latest YoY (%)
Net Cash Generated from Operating Activities (A) 3,940.02 5,004.98 -21.28%
Purchase of Property, Plant and Equipment (CapEx) 1,599.33 1,162.16 +37.62%
Purchase of Intangibles & Intangible Assets Under Development -1,479.98 -386.04 +283.37%
Proceeds from Sale of PPE & Intangibles 67.61 33.40 +102.43%
Purchase of Investments & Subsidiary/Associate Acquisition -56.99 -2,323.00 -97.55%
Other Investing Cash Flows (Interest, Rent, Bank Balances) 742.56 146.66 +406.31%
Net Cash Used in Investing Activities (B) -2,326.13 -3,691.14 -36.98%
Proceeds / (Repayment) of Borrowings (Net) 187.78 -86.05 N/M
Payment of Lease Liabilities & Finance Interest -144.85 -116.61 +24.22%
Dividends Paid to Shareholders -1,292.40 -1,049.83 +23.11%
Other Financing Activities (Option Settlement, Shares Issue) 15.82 -40.30 N/M
Net Cash Used in Financing Activities (C) -1,233.65 -1,292.79 -4.57%
Net Increase in Cash & Cash Equivalents (A + B + C) 380.24 21.05 +1706.37%
Cash & Cash Equivalents at Beginning of Year 542.65 512.34 +5.92%
Effect of Exchange Rate Changes on Cash Balances 92.50 9.26 +898.92%
Cash & Cash Equivalents at End of Year (Statement of Cash Flows) 1,015.39 542.65 +87.12%

Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange

Cipla’s capital allocation strategy prioritises organic capacity augmentation, R&D innovation, and strategic inorganic deals:

  • CapEx & CWIP Investments: Total capital expenditure for FY 2025–26 stood at ₹3,079.31 Crores (comprising ₹1,599.33 Crores in property, plant & equipment and ₹1,479.98 Crores in intangible assets/in-licensing acquisitions). Capital Work-in-Progress (CWIP) reached ₹1,586.28 Crores, driven by greenfield respiratory API expansion at Kurkumbh, oncology API expansion at Bommasandra, new MDI lines at Fall River (US) and Goa, and FFS respule capacity in Sikkim.
  • R&D Expenditure & Intensity: Total consolidated R&D expenditure reached ₹1,974.00 Crores (7.0% of revenue) in FY 2025–26, up 28.52% from ₹1,536.00 Crores (5.6% of revenue) in FY 2024–25. Standalone R&D expenditure stood at ₹1,618.47 Crores (8.53% of standalone revenue).
  • Foreign Exchange Earnings & Outgo (Standalone): Total foreign exchange earned amounted to ₹9,144.72 Crores (including export sales of ₹6,711.08 Crores and royalty/licensing income of ₹1,310.32 Crores). Total foreign exchange outgo was ₹4,225.96 Crores, resulting in a net foreign exchange surplus of ₹4,918.76 Crores.

👥 Power & Control: Cipla Governance, Leadership & Shareholding Pattern

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

Cipla’s Board of Directors comprises an experienced mix of executive leadership, promoter stewards, and independent corporate leaders:

Name of Director / KMP Designation / Role DIN Category
Dr. Y. K. Hamied Non-Executive Chairman 00029049 Promoter & Non-Executive Director
Mr. P. R. Ramesh Vice-Chairman & Lead Independent Director 01915274 Independent Director
Mr. Achin Gupta Managing Director & Global CEO (MD & GCEO) 09491674 Executive Director (w.e.f. April 1, 2026)
Mr. Kamil Hamied Non-Executive Director 00024292 Promoter & Non-Executive Director
Mr. Adil Zainulbhai Non-Executive Director 06646490 Non-Executive Director (Retiring by Rotation)
Mr. Abhijit Joshi Non-Executive Director 07115673 Non-Executive Director
Dr. Balram Bhargava Independent Director 10479707 Independent Director
Dr. Mandar Vaidya Independent Director 09690327 Independent Director (Chairperson – IRMC)
Ms. Maya Hari Independent Director 01123969 Independent Director (Chairperson – NRC)
Ms. Sharmila Paranjpe Independent Director 02328770 Independent Director
Mr. Ashish Adukia Global Chief Financial Officer (CFO) – Key Managerial Personnel (KMP)
Mr. Rajendra Chopra Company Secretary & Compliance Officer – Key Managerial Personnel (KMP)

Who Owns the Stock? Shareholding Pattern

As of March 31, 2026, Cipla Limited’s paid-up share capital of ₹161.56 Crores is divided into 80,77,82,631 equity shares of face value ₹2 each, held across 5,98,053 shareholder folios:

Shareholder Category Number of Shares Held % of Total Issued Shares
Promoter & Promoter Group 23,52,87,003 29.12%
Mutual Funds (Domestic DIIs) 15,02,64,666 18.60%
Insurance Companies, Banks & FIs 9,08,71,547 11.25%
Foreign Institutional Investors (FPIs/FIIs) 18,16,69,955 22.49%
Resident Individuals (Public) 11,25,54,749 13.93%
Others (Bodies Corporate, Trusts, Clearing Members) 3,47,34,542 4.30%
Global Depository Receipts (GDRs) 24,00,169 0.30%
Total Share Capital 80,77,82,631 100.00%

Major institutional and individual shareholders holding more than 1% of the equity share capital include:

  • Dr. Y. K. Hamied: 15,05,21,183 shares (18.63%)
  • Life Insurance Corporation of India (LIC): 7,74,65,141 shares (9.59%)
  • Ms. Sophie Ahmed: 4,59,82,000 shares (5.69%)
  • HDFC Mutual Fund: 3,50,20,124 shares (4.34%)
  • Mr. M. K. Hamied: 2,78,44,320 shares (3.45%)
  • SBI Mutual Fund: 2,38,59,595 shares (2.95%)
  • ICICI Prudential Mutual Fund: 1,93,24,659 shares (2.39%)
  • DSP Mutual Fund: 1,43,07,255 shares (1.77%)
  • Nippon Mutual Fund: 1,36,15,393 shares (1.69%)
  • Parag Parikh Mutual Fund: 1,35,94,444 shares (1.68%)
  • NPS Trust: 1,35,81,975 shares (1.68%)
  • Government Pension Fund Global: 1,10,70,223 shares (1.37%)
  • Mr. Kamil Hamied: 1,09,39,500 shares (1.35%)
  • Vanguard Total International Stock Index Fund: 81,81,015 shares (1.01%)

🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

Cipla Limited’s consolidated financial statements incorporate key operating subsidiaries and associates pursuant to Ind AS 110 and Ind AS 28:

Entity Name Relationship Country of Incorporation % Shareholding FY 2025-26 Turnover (₹ Cr) FY 2025-26 Net PAT (₹ Cr)
Cipla Health Limited Wholly Owned Subsidiary India 100.00% 1,120.45 42.18
Inzpera Healthsciences Limited Wholly Owned Subsidiary India 100.00% 85.60 6.42
Cipla (EU) Limited Wholly Owned Subsidiary United Kingdom 100.00% 2,450.12 182.30
InvaGen Pharmaceuticals Inc. Wholly Owned Subsidiary USA 100.00% 3,120.80 210.45
Cipla Medpro South Africa (Pty) Ltd Wholly Owned Subsidiary South Africa 100.00% 3,850.10 312.60
Jay Precision Pharmaceuticals Pvt Ltd Subsidiary India 74.00% 153.19 38.64
Cipla Maroc SA Subsidiary Morocco 60.00% 270.11 45.81
Aspergen Inc. Subsidiary USA 60.00% 0.00 -110.83
Stempeutics Research Pvt Ltd Associate India 34.36% 12.40 -3.46
GoApptiv Private Limited Associate India 22.99% 76.90 0.57
Brandmed (Pty) Limited Associate South Africa 30.00% 31.62 -0.08
MKC Biotherapeutics Inc. Associate / JV USA 34.40% 23.52 -7.75
iCaltech Innovations Pvt Ltd Associate India 20.00% 5.01 -0.12

Strategic Investments, Credit Ratings, & Contingent Liabilities

Cipla’s capital structure and balance sheet protections are reinforced by treasury investments, high credit ratings, and proactive litigation management:

  • Credit Ratings: India Ratings and Research affirmed Cipla’s Commercial Paper rating at IND A1+ / IND AAA (Stable). CARE Ratings reaffirmed long-term/short-term bank facility limits at CARE A1+ / CARE AAA (Stable).
  • Contingent Liabilities (Note 44): Total contingent liabilities not provided for stand at ₹739.75 Crores as of March 31, 2026 (up from ₹660.73 Crores in FY25), comprising claims against the group not acknowledged as debt (₹139.04 Crores), income tax disallowances under dispute (₹211.69 Crores), and excise/service tax/GST valuation claims (₹387.46 Crores).
  • DPCO Price Overcharge Dispute: The company continues to contest demand notices from the National Pharmaceutical Pricing Authority (NPPA) under DPCO-1995 aggregating to ₹2,011 Crores (Principal: ₹863 Crores, Interest: ₹1,148 Crores). Cipla has voluntarily deposited ₹202.15 Crores under protest (₹175.08 Crores in 2003 and ₹27.07 Crores in July 2025). Supported by legal opinion, management expects a favorable outcome before the Supreme Court and Bombay High Court and has determined no additional provision is necessary.
  • Capital Commitments: Estimated value of contracts remaining to be executed on capital account and not provided for stands at ₹2,523.42 Crores as of March 31, 2026.

🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs

Competitive Advantages & Economic Moats

Cipla holds structural competitive moats across the global pharmaceutical landscape:

  • Inhalation & Respiratory Mastery: Nine decades of drug-device integration expertise across MDIs, DPIs, Respules, and Nasal Sprays, backed by dedicated manufacturing sites in Goa, Indore, Fall River (US), and Long Island (US).
  • Unrivalled Indian Commercial Scale: #1 position in IPM respiratory care (~26% share), #1 in urology, top-2 in diabetes, and top-3 in cardiometabolic care. Anchored by 33 brands exceeding ₹100 Crores in annual turnover and an expansive trade generics distribution network reaching 1.5 Lakh+ retail pharmacies.
  • Partner of Choice for Global Innovators: Established in-licensing and commercial partnership ecosystem with global MNCs including Eli Lilly (Yurpeak / Tirzepatide), MannKind (Afrezza / Inhaled Insulin), Pfizer (multi-year distribution for 4 major brands), Roche (Oncology), Sanofi (Anti-epilepsy), and Novartis (Galvus acquisition).
  • Fortress Balance Sheet: Net cash positive balance sheet with total liquid cash and investment balances of ₹11,140 Crores, low debt-to-equity ratio (0.02x), and strong operating cash generation (₹3,940.02 Crores in FY26).

What Could Go Wrong? Key Challenges & Business Risks

Cipla’s long-term operational performance remains exposed to several industry and geographic risks:

  • Regulatory & USFDA Compliance Risks: Regulatory inspection outcomes or import alerts at internal sites or third-party contract manufacturers (e.g., Pharmathen International S.A. import alert impacting Lanreotide supply in North America) can disrupt commercial product availability and revenue growth.
  • US Price Erosion & Competition: Accelerated pricing pressure in US generic markets, heightened competitor launches in inhalation products, and regulatory delays in securing final ANDA approvals for complex assets (e.g., gSymbicort, gAdvair).
  • Domestic Price Controls (NLEM / DPCO): Potential expansion of the National List of Essential Medicines (NLEM) by the Ministry of Health and Family Welfare can impose ceiling prices on key chronic formulations, capping profit margins.
  • Geopolitical & Currency Volatility: Supply chain bottlenecks in Middle East transit corridors, foreign exchange illiquidity in select African markets, and input vendor dependence for critical APIs/valves.

The Next Chapter: Strategic Priorities & CapEx Initiatives

Under ‘Project Prism’ and its ‘Strategic Vision 2031’, Cipla is executing targeted growth initiatives:

  • India Strategic Aspiration: Aspire to achieve the #2 overall position in the Indian Pharmaceutical Market (IPM) by scaling core chronic therapies, expanding the Breathefree Lung Wellness diagnostic centers, accelerating Consumer Health digital penetration, and driving pediatric/wellness offerings through Inzpera.
  • North America Respiratory Leadership: Build the #1 Respiratory Prescription portfolio in the US across MDIs, DPIs, and Respules, driven by commercial scaling of approved gVentolin, upcoming launches of gSymbicort and gAdvair, and transition towards green low-GWP propellant inhalers (R152a).
  • Next-Generation Modalities & Biosimilars: Expand presence in biosimilars (Filgrastim commercialisation and Kemwell JV pipeline), advance cell & gene therapy (CAR-T partnership with ImmunoACT for Africa), and leverage the newly established mRNA R&D center in Germany (CiplaRna GmbH).
  • Digital & AI-Driven Transformation: Accelerating Industry 4.0 adoption across manufacturing facilities, GenAI-driven quality documentation, predictive batch execution, and automated supply chain demand forecasting.

The Verdict: Strategic Outlook & Conclusion

Cipla Limited stands at a pivotal moment as it celebrates 90 years of healthcare impact. Guided by a fortress net-cash balance sheet (₹34,520.24 Crores Total Equity), market-leading positions across home markets in India and South Africa, a expanding US inhalation pipeline, and structural partnerships with global pharma leaders, Cipla remains uniquely insulated against generic commoditisation. As executive leadership transitions smoothly to MD & Global CEO Mr. Achin Gupta, Cipla is well positioned to sustain high-return compounding while advancing its purpose of ‘Caring for Life’.

Frequently Asked Questions (FAQs) About Cipla Limited

Q1: What does Cipla manufacture, and what are its flagship brands?

Cipla manufactures and commercialises over 1,500 pharmaceutical products across 50+ dosage forms, including metered-dose inhalers, dry powder inhalers, respules, oral solids, liquids, nasal sprays, injectables, and Active Pharmaceutical Ingredients (APIs). Its flagship brands include Foracort (the first brand in India to cross ₹1,000 Crores in annual market sales), Duolin, Budecort, Dytor (₹650 Cr+ cardiac brand), Montair LC, and consumer health leaders Omnigel, Nicotex, Cipladine, Cofsils, and Prolyte.

Q2: What were Cipla’s revenue and net profit in FY 2025-26?

In FY 2025-26, Cipla reported consolidated Revenue from Operations of ₹28,162.59 Crores (up 2.23% YoY from ₹27,547.62 Crores in FY 2024-25) and a Consolidated Net Profit After Tax (attributable to owners) of ₹3,879.23 Crores (with Diluted EPS of ₹48.00 per share).

Q3: Who are the promoters and Managing Director of Cipla Limited?

Cipla is promoted by the Hamied family (Dr. Y. K. Hamied, Mr. M. K. Hamied, Ms. Sophie Ahmed, and Mr. Kamil Hamied), holding a combined 29.12% equity stake. The Non-Executive Chairman is Dr. Y. K. Hamied. Effective April 1, 2026, Mr. Achin Gupta assumed office as the Managing Director and Global Chief Executive Officer (MD & GCEO), succeeding Mr. Umang Vohra.

Q4: Where are Cipla’s manufacturing facilities located, and what is its export revenue share?

Cipla operates 48 cGMP-compliant manufacturing facilities globally across 5 countries (39 in India including Goa, Patalganga, Kurkumbh, Indore, Sikkim, and Baddi; and 9 international plants in the US, South Africa, Morocco, and China). International exports and overseas operating entities contribute 54.98% of total consolidated revenues.

Q5: What is Cipla’s financial leverage, net worth, and credit rating?

Cipla maintains a net-cash positive balance sheet with total liquid cash and investment balances of ₹11,140 Crores and total consolidated equity (Net Worth) of ₹34,520.24 Crores as of March 31, 2026. Its credit ratings are held at the highest investment grade: CARE A1+ / CARE AAA (Stable) by CARE Ratings and IND A1+ / IND AAA (Stable) by India Ratings.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.cipla.com